MicroRNAs modulation and clinical outcomes at 1 year of follow-up in obese patients with pre-diabetes treated with metformin vs. placebo.
Inflammation
Metformin
MicroRNAs
Obesity
Oxidative stress
Pre-diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
26
01
2021
accepted:
10
05
2021
pubmed:
20
5
2021
medline:
26
11
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Obese pre-diabetics over express cytokines that influence myocardial function via microRNAs (miRs) expression. To evaluate inflammatory/oxidative stress, miRs' expression and cardiovascular function in obese pre-diabetics assigned to metformin therapy vs. placebo vs. normo-glycemics at 12 months of follow-up. Eighty-three obese patients after abdominoplastic surgery were divided in pre-diabetics (n 55), normo-glycemics (n 28), and assigned to hypocaloric diet. Pre-diabetics were assigned to metformin (n 23) or to placebo (n 22) plus hypocaloric diet. Obese pre-diabetics in metformin vs. placebo, and obese pre-diabetics with placebo vs. normoglycemics, had significant differences about IMT, MPI, and LVM (p < 0.05). Obese pre-diabetics in metformin vs. placebo showed significant reduction in serum miR-195 and miR-27 (p < 0.05). Obese pre-diabetics in metformin vs. normoglycemics showed higher expression of serum miR-195 and miR-27 (p < 0.05). Finally, we found inverse relation between IMT and insulin, HOMA-IR, miR-195, miR-27; between LVEF and Insulin, HOMA-IR, miR-195 and miR-27. We found inverse correlation between LVM and sirtuin-1, Insulin, HOMA-IR, miR-195 and miR-27, and direct correlation with interleukin-6. MPI inversely linked to miR-195 and miR-27. In obese pre-diabetics', metformin significantly reduces inflammation/oxidative stress, and miR-195 and miR-27, with reduction in LVM, IMT.
Sections du résumé
BACKGROUNDS
BACKGROUND
Obese pre-diabetics over express cytokines that influence myocardial function via microRNAs (miRs) expression.
OBJECTIVES
OBJECTIVE
To evaluate inflammatory/oxidative stress, miRs' expression and cardiovascular function in obese pre-diabetics assigned to metformin therapy vs. placebo vs. normo-glycemics at 12 months of follow-up.
MATERIALS AND METHODS
METHODS
Eighty-three obese patients after abdominoplastic surgery were divided in pre-diabetics (n 55), normo-glycemics (n 28), and assigned to hypocaloric diet. Pre-diabetics were assigned to metformin (n 23) or to placebo (n 22) plus hypocaloric diet.
RESULTS
RESULTS
Obese pre-diabetics in metformin vs. placebo, and obese pre-diabetics with placebo vs. normoglycemics, had significant differences about IMT, MPI, and LVM (p < 0.05). Obese pre-diabetics in metformin vs. placebo showed significant reduction in serum miR-195 and miR-27 (p < 0.05). Obese pre-diabetics in metformin vs. normoglycemics showed higher expression of serum miR-195 and miR-27 (p < 0.05). Finally, we found inverse relation between IMT and insulin, HOMA-IR, miR-195, miR-27; between LVEF and Insulin, HOMA-IR, miR-195 and miR-27. We found inverse correlation between LVM and sirtuin-1, Insulin, HOMA-IR, miR-195 and miR-27, and direct correlation with interleukin-6. MPI inversely linked to miR-195 and miR-27.
CONCLUSIONS
CONCLUSIONS
In obese pre-diabetics', metformin significantly reduces inflammation/oxidative stress, and miR-195 and miR-27, with reduction in LVM, IMT.
Identifiants
pubmed: 34009437
doi: 10.1007/s00592-021-01743-5
pii: 10.1007/s00592-021-01743-5
doi:
Substances chimiques
MIRN195 microRNA, human
0
MicroRNAs
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1381-1393Informations de copyright
© 2021. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
Sardu C, Pieretti G, D’Onofrio N et al (2018) Inflammatory Cytokines and SIRT1 levels in subcutaneous abdominal fat: relationship with cardiac performance in overweight pre-diabetics patients. Front Physiol 9:1030
doi: 10.3389/fphys.2018.01030
Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtuins as regulators of metabolism and health span. Nat Rev Mol Cell Biol 13(4):225–238
doi: 10.1038/nrm3293
Rappou E, Jukarainen S, Rinnankoski-Tuikka R et al (2016) Weight loss is associated with increased NAD(+)/SIRT1 expression but Reduced PARP activity in white adipose tissue. J Clin Endocrinol Metab 101(3):1263–1273
doi: 10.1210/jc.2015-3054
Lorente-Cebriàn S, Gonzàlez-Muniesa P, Milagro FI, Martinez JA (2019) MicroRNAs and other non-coding RNAs in adipose tissue and obesity: emerging roles as biomarkers and therapeutic. ClinSci (Lond) 133(1):23–40
doi: 10.1042/CS20180890
Kuryłowicz A, Wicik Z, Owczarz M, Jonas MI, Kotlarek M, Świerniak M, Lisik W, Jonas M, Noszczyk B, Puzianowska-Kuźnicka M (2018) NGS reveals molecular pathways affected by obesity and weight loss-related changes in miRNA levels in adipose tissue. Int J Mol Sci 19(1):66
doi: 10.3390/ijms19010066
Chen T, Zhang Y, Liu Y, Zhu D, Yu J, Li G, Sun Z, Wang W, Jiang H, Hong Z (2019) MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging Albany NY. 11(18): 7510–7524.
Mortuza R, Feng B, Chakrabarti S (2014) miR-195 Regulates SIRT1-mediated Changes in Diabetic Retinopathy. Diabetologia 57(5):1037–1046
doi: 10.1007/s00125-014-3197-9
Wang L, Qin D, Shi H, Zhang Y, Li H, Han Q (2019) MiR-195-5p Promotes Cardiomyocyte Hypertrophy by Targeting MFN2 and FBXW7. Biomed Res Int 2019:1580982
pubmed: 31341888
pmcid: 6614993
Demirsoy IH, Ertural DY, Balci S, Çınkır U, Sezer K, Tamer L, Aras N (2018) Profiles of circulating MiRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem 37(4):499–506
doi: 10.2478/jomb-2018-0009
Standards of Medical Care in Diabetes (2017) Diabetes Care 40(Suppl. 1):S1–S2.
Mohan M, Al-Talabany S, McKinnie A et al (2019) A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J 40(1):3409–3417
doi: 10.1093/eurheartj/ehz203
Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16(3):233–271
doi: 10.1093/ehjci/jev014
de Simone G, Daniels SR, Devereux RB et al (1992) Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and the impact of overweight. J Am Coll Cardiol 20:1251–1260
doi: 10.1016/0735-1097(92)90385-Z
Stein JH, Korcarz CE, Hurst RT et al (2008) Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American society of echocardiography carotid intima-media thickness task force. J Am Soc Echocardiogr 21:93–111
doi: 10.1016/j.echo.2007.11.011
Marfella R, Di Filippo C, Potenza N et al (2013) Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail 15(11):1277–1288
doi: 10.1093/eurjhf/hft088
D’Onofrio N, Pieretti G, Ciccarelli F et al (2019) Abdominal fat SIRT6 expression and its relationship with inflammatory and metabolic pathways in pre-diabetic overweight patients. Int J Mol Sci 20(5):1153
doi: 10.3390/ijms20051153
Arner P, Kulyté A (2015) MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol 11(5):276–288
doi: 10.1038/nrendo.2015.25
Mortuza R, Feng B, Chakrabarti S (2014) miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 57:1037–1046
doi: 10.1007/s00125-014-3197-9
Zhang Y, Sun X, Icli B, Feinberg MW (2017) Emerging roles for MicroRNAs in diabetic microvascular disease: novel targets for therapy. Endocrine Rev 38(2):145–168
doi: 10.1210/er.2016-1122
Zheng D, Ma J, Yu Y et al (2015) Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia 58:1949–1958
doi: 10.1007/s00125-015-3622-8
Ahmed FW, Bakhashab S, Bastaman IT, Crossland RE, Glanville M, Weaver JU (2018) Anti-Angiogenic miR-222, miR-195, and miR-21a plasma levels in T1DM are improved by metformin therapy, thus elucidating its cardioprotective effect: the MERIT study. Int J Mol Sci 19(10):3242
doi: 10.3390/ijms19103242
Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z (2009) A role of miR-27 in the regulation of adipogenesis. FEBS J 276(8):2348–2358
doi: 10.1111/j.1742-4658.2009.06967.x
Karolina DS, Tavintharan S, Armugam A et al (2012) Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97(12):E2271–E2276
doi: 10.1210/jc.2012-1996
Babaee M, Chamani E, Ahmadi R et al (2020) The expression levels of miRNAs- 27a and 23a in the peripheral blood mononuclear cells (PBMCs) and their correlation with FOXO1 and some inflammatory and anti-inflammatory cytokines in the patients with coronary artery disease (CAD). Life Sci 256:11789
doi: 10.1016/j.lfs.2020.117898
Chen T, Zhang Yi, Liu Y et al (2019) MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging (Albany NY) 11(18):7510–7524
doi: 10.18632/aging.102263